ArticleNucleic acids research1993
The major histocompatibility complex (MHC) Ea promoter: sequences and factors at the initiation site.
Article in Nucleic acids research, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Nucleosome eviction from MHC class II promoters controls positioning of the transcription start site.Nucleic acids research · 2009Article
- Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters.Nucleic acids research · 2006Article
- Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.Molecular and cellular biology · 2002Article
- Regulation of the juvenile hormone esterase gene by a composite core promoter.The Biochemical journal · 2000Article
- Article
- Transcription of the juvenile hormone esterase gene under the control of both an initiator and AT-rich motif.The Biochemical journal · 1998Article
- CCAAT binding NF-Y-TBP interactions: NF-YB and NF-YC require short domains adjacent to their histone fold motifs for association with TBP basic residues.Nucleic acids research · 1997Article
- Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.Molecular and cellular biology · 1996Article
- The major histocompatibility complex class II Ea promoter requires TFIID binding to an initiator sequence.Molecular and cellular biology · 1996Article
- The function of the octamer-binding site in the DRA promoter.Immunogenetics · 1996Article
- CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA.Nucleic acids research · 1995Article
- Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription.Nucleic acids research · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have analysed the function of sequences in the TATA/initiator region of the promoter of Ea, a class II gene of the Major Histocompatibility Complex. We find that the Ea promoter contains an initiator element with a strong influence on transcription. We also find that the Ea promoter does contain a bona fide TATA box, which can be recognized by the TATA binding protein (TBP), and that TBP is required for transcriptional activity. For activity, TBP must be included within a larger TFIID complex, as Ea transcription in a heat-treated extract can be restored by immunopurified TFIID but not by TBP alone. On the other hand, the TATA motif can be eliminated without significantly affecting either the efficiency or the startsites of transcription. This suggests that TBP, even in this TATA-containing promoter, is held in place by other components of the initiation complex, regardless of its affinity for the underlying DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.